RE:Zypitamag sales continues to accelerateProblem with your thesis is that if you look at their last few cash flow statements, they have not been making their payments to the Company that sold them Zypitimag and, in the note, looks like they owe close to $500,000 in royalties. Likely if they had made these payments they would be out of cash...and no money to support any R+D. By Q3, Aggrastate selling price will be under pressure and decline rapidly as it already has. The problem is this Company will find a way to screw up...like it did with the company it invested in for $10 Million and then wrote it off the same year.